DIAmond Sessions
Conversations on Today’s Priorities!
DIAmond Sessions represent rare opportunities for deeper connection with regulatory leadership through insightful dialogue. Join us in San Diego, CA to help chart new horizons and processes toward the interconnected future of global health.
DIA 2024 DIAmond Sessions will allow for deeper discussions into critical themes from the keynote plenary session. Expect thought-provoking conversations around some of the major themes of DIA 2024, including an exploration of combination products, AI and innovation, and what is happening with regulatory convergence.
-
Monday, June 17
11:00AM -12:00PM
Navigating the Trusted, Responsible, and Ethical Horizon of Artificial Intelligence: Uniting Healthcare Perspectives
In the rapidly evolving landscape of healthcare, the integration of artificial intelligence (AI) brings forth unprecedented opportunities and challenges. As we stand at the crossroads of using AI ethically and building it responsibly, it becomes imperative to foster a collaborative dialogue that transcends healthcare boundaries. Join us for a thought-provoking DIAmond session where key stakeholders from technology companies, pharmaceuticals, patient advocacy groups, academia/researchers, and more converge to explore the responsible, trusted, equitable, and ethical use and ethical dimensions of AI in healthcare.
Session Chair and Speakers
Dave deBronkart
Patient Advocate, E-Patient Dave, LLC
Junaid Bajwa
Practicing Physician, UK’s National Health Service; Chief Medical Scientist, Microsoft Research, United Kingdom
Karla Childers
Head, Bioethics-Based Science and Technology Policy, Johnson & Johnson
Martin Hodosi
Partner, Healthcare and Life Sciences Practices, Kearney, United Kingdom
-
Tuesday, June 18
10:00-11:00AM International Regulatory Convergence: Regulatory Science to Address Challenges Brought by Pharmaceutical Innovation
Innovative approaches have the potential to create new opportunities for patients, but they also bring challenges to regulators, called to evaluate, and supervise products for which traditional regulatory approaches might not be appropriate. Global regulators will discuss how regulatory science is key to develop solutions and how regulators worldwide need to work together to overcome such challenges.
Session Chair and Speakers
Emer Cooke
Executive Director, Chair, ICMRA, The European Medicines Agency, Netherlands
Yasuhiro Fujiwara
Chief Executive, Pharmaceuticals and Medical Devices Agency (PMDA), Japan
-
Wednesday, June 19
10:00-11:00AM Pioneering New Frontiers: Advanced Drug Delivery Technologies and Cell/Gene Therapies in Combination Products
In the rapidly evolving landscape of healthcare, the integration of artificial intelligence (AI) brings forth unprecedented opportunities and challenges. As we stand at the crossroads of using AI ethically and building it responsibly, it becomes imperative to foster a collaborative dialogue that transcends healthcare boundaries. Join us for a thought-provoking DIAmond session where key stakeholders from technology companies, pharmaceuticals, patient advocacy groups, academia/researchers, and more converge to explore the responsible, trusted, equitable, and ethical use and ethical dimensions of AI in healthcare.
Session Chair and Speakers
James Wabby
Global Head, Regulatory Affairs, Emerging Technologies and Combination Products, AbbVie
William Daunch
Chief Technology Officer, Focal Medical, Inc.
Andrea Gray
Biomedical Engineer Advisor, CBER, FDA
Michael Lehmicke
Senior Vice President, Science and Industry Affairs, Alliance for Regenerative Medicine
Rob Schulz
Vice President, Clinical Research, TA Lead, Neuromuscular Disease, Cytokinetics